Acetaminophen influences musculoskeletal signaling but not adaptations to endurance exercise training.
Brandon M RobertsAlyssa V GeddisAlexandra CiuciuMarinaliz ReynosoNikhil MehtaAlyssa N VaranoskeAlyssa M KelleyRaymond J WalkerRigoberto MunozAlexander L KolbJeffery S StaabMarshall A NaimoRyan E TomlinsonPublished in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2024)
Acetaminophen (ACE) is a widely used analgesic and antipyretic drug with various applications, from pain relief to fever reduction. Recent studies have reported equivocal effects of habitual ACE intake on exercise performance, muscle growth, and risks to bone health. Thus, this study aimed to assess the impact of a 6-week, low-dose ACE regimen on muscle and bone adaptations in exercising and non-exercising rats. Nine-week-old Wistar rats (n = 40) were randomized to an exercise or control (no exercise) condition with ACE or without (placebo). For the exercise condition, rats ran 5 days per week for 6 weeks at a 5% incline for 2 min at 15 cm/s, 2 min at 20 cm/s, and 26 min at 25 cm/s. A human equivalent dose of ACE was administered (379 mg/kg body weight) in drinking water and adjusted each week based on body weight. Food, water intake, and body weight were measured daily. At the beginning of week 6, animals in the exercise group completed a maximal treadmill test. At the end of week 6, rats were euthanized, and muscle cross-sectional area (CSA), fiber type, and signaling pathways were measured. Additionally, three-point bending and microcomputer tomography were measured in the femur. Follow-up experiments in human primary muscle cells were used to explore supra-physiological effects of ACE. Data were analyzed using a two-way ANOVA for treatment (ACE or placebo) and condition (exercise or non-exercise) for all animal outcomes. Data for cell culture experiments were analyzed via ANOVA. If omnibus significance was found in either ANOVA, a post hoc analysis was completed, and a Tukey's adjustment was used. ACE did not alter body weight, water intake, food intake, or treadmill performance (p > .05). There was a treatment-by-condition effect for Young's Modulus where placebo exercise was significantly lower than placebo control (p < .05). There was no treatment by condition effects for microCT measures, muscle CSA, fiber type, or mRNA expression. Phosphorylated-AMPK was significantly increased with exercise (p < .05) and this was attenuated with ACE treatment. Furthermore, phospho-4EBP1 was depressed in the exercise group compared to the control (p < .05) and increased in the ACE control and ACE exercise group compared to placebo exercise (p < .05). A low dose of ACE did not influence chronic musculoskeletal adaptations in exercising rodents but acutely attenuated AMPK phosphorylation and 4EBP1 dephosphorylation post-exercise.
Keyphrases
- high intensity
- body weight
- resistance training
- angiotensin ii
- angiotensin converting enzyme
- physical activity
- low dose
- skeletal muscle
- endothelial cells
- healthcare
- double blind
- cross sectional
- placebo controlled
- clinical trial
- public health
- spinal cord injury
- oxidative stress
- chronic pain
- body composition
- induced apoptosis
- bone mineral density
- randomized controlled trial
- climate change
- health information
- spinal cord
- blood pressure
- artificial intelligence
- big data
- high dose
- open label
- electronic health record
- middle aged
- deep learning
- body mass index
- data analysis
- endoplasmic reticulum stress
- pluripotent stem cells